|
Rensselaer Professor Robert Linhardt Wins American Chemical Society’s Wolfrom Award
Rensselaer Polytechnic Institute Professor Robert Linhardt
has won the 2010 Melville L. Wolfrom Award from the American
Chemical Society (ACS) Division of Carbohydrate Chemistry.
The organization will honor Linhardt, the Ann and John H.
Broadbent Jr. ’59 Senior Constellation Professor of
Biocatalysis and Metabolic Engineering at Rensselaer, in August
at the Fall 2010 ACS National Exposition in Boston.
“The ACS Wolfrom Award is a well-deserved honor for Dr.
Linhardt, a true leader in the carbohydrate chemistry field,”
said Jonathan Dordick, the Howard P. Isermann ’42 Professor of
Chemical and Biological Engineering and director of the Center
for Biotechnology and Interdisciplinary Studies at Rensselaer.
“Bob is a pre-eminent scientist, researcher, teacher, and
inventor. He is a pioneer and an innovator, and his work
continues to be at the forefront of fundamental discoveries and
applications that impact society. He is an innovator who has
created techniques that employ the most unique solutions to
real-world problems. We are truly fortunate to have Bob at
Rensselaer.”
Linhardt has made significant contributions in boosting the
safety of the blood thinner heparin, helping discover in 2008 a
contaminant in the drug that resulted in hundreds of patients
falling ill. He is also leading the effort to create a safer,
non-animal-derived, synthetic alternative to heparin.
Linhardt and Jian Liu at the University of North Carolina
discovered the “recipe” for synthetic heparin three years ago.
At the ACS National Exposition in August 2008, Linhardt
announced his team’s success in constructing minuscule
carbohydrates into a purer, safer alternative — creating the
first fully synthetic heparin, and the largest amount ever
created in the laboratory.
With Linhardt’s discovery, a fully synthetic heparin can be
created in a pharmaceutical manufacturing environment, giving
drug manufacturers extreme control over the safety and purity
of the product. He has said the drug could advance to human
clinical trials within five years.
Government agencies and many foundations and corporations
have provided extensive funding for Linhardt’s research. An
active contributor to professional publications, Linhardt has
served on the editorial board of such top journals as the
Journal of Biological Chemistry, Applied
Biochemistry and Biotechnology, and the Journal of
Carbohydrate Chemistry. He has published more than 450
research papers and holds 45 patents. In 2009, Linhardt was one
of 10 people— alongside U.S. President Barack Obama and
business leader Bill Gates—recognized by Scientific
American for his “demonstrated outstanding commitment to
assuring that the benefits of new technologies and knowledge
will accrue to humanity.”
After 21 years on the faculty of the University of Iowa,
Linhardt joined Rensselaer in 2003 as a senior constellation
professor. He earned his master’s and doctoral degrees in
organic chemistry from the Johns Hopkins University and a
bachelor’s degree in chemistry from Marquette University.
|
Published
April 1,
2010 |
Contact: Michael Mullaney
Phone: (518) 276-6161
E-mail: mullam@rpi.edu |
|